Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan.

Trial Profile

Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Anakinra (Primary)
  • Indications Fever; Mucositis
  • Focus Adverse reactions
  • Acronyms AFFECT-1
  • Most Recent Events

    • 05 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Feb 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 25 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top